» Articles » PMID: 34545128

The Rs9340799 Polymorphism of the Estrogen Receptor Alpha (ESR1) Gene and Its Association with Breast Cancer Susceptibility

Overview
Journal Sci Rep
Specialty Science
Date 2021 Sep 21
PMID 34545128
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

The ESR1 rs9340799 polymorphism has been frequently investigated with regard to its association with breast cancer (BC) susceptibility, but the findings have been inconclusive. In this work, we aimed to address the inconsistencies in study findings by performing a systematic review and meta-analysis. Eligible studies were identified from the Web of Science, PubMed, Scopus, China National Knowledge Infrastructure, VIP and Wanfang databases based on the predefined inclusion and exclusion criteria. The pooled odds ratio (OR) was then calculated under five genetic models: homozygous (GG vs. AA), heterozygous (AG vs. AA), dominant (AG + GG vs. AA), recessive (GG vs. AA + AG) and allele (G vs. A). Combined results from 23 studies involving 34,721 subjects indicated a lack of significant association between the polymorphism and BC susceptibility (homozygous model, OR = 1.045, 95% CI 0.887-1.231, P = 0.601; heterozygous model, OR = 0.941, 95% CI 0.861-1.030, P = 0.186; dominant model, OR = 0.957, 95% CI 0.875-1.045, P = 0.327; recessive model, OR = 1.053, 95% CI 0.908-1.222, P = 0.495; allele model, OR = 0.987, 95% CI 0.919-1.059, P = 0.709). Subgroup analyses by ethnicity, menopausal status and study quality also revealed no statistically significant association (P > 0.05). In conclusion, our results showed that the ESR1 rs9340799 polymorphism was not associated with BC susceptibility, suggesting its limited potential as a genetic marker for BC.

Citing Articles

Association of ESR1 Polymorphisms with Susceptibility to Migraine: A Meta-Analysis and Trial Sequential Analysis.

Ranjan S, Paikaray A, Mishra A, Sethi A, Dhurua D, Panda A Curr Pain Headache Rep. 2025; 29(1):41.

PMID: 39878792 DOI: 10.1007/s11916-024-01338-z.


Emerging roles of CircRNA-miRNA networks in cancer development and therapeutic response.

Hashemi M, Khosroshahi E, Daneii P, Hassanpoor A, Eslami M, Koohpar Z Noncoding RNA Res. 2024; 10:98-115.

PMID: 39351450 PMC: 11440256. DOI: 10.1016/j.ncrna.2024.09.006.


Analysis of Single Nucleotide Polymorphisms (SNPs) rs2234693 and rs9340799 of the Gene and the Risk of Breast Cancer.

Smolarz B, Nowak A, Brys M, Forma E, Lukasiewicz H, Samulak D In Vivo. 2024; 38(5):2134-2143.

PMID: 39187368 PMC: 11363788. DOI: 10.21873/invivo.13676.


Genetic Variants Associated With Response to Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer Patients: A Field Synopsis and Meta-Analysis.

Sito H, Sharzehan M, Islam M, Tan S Br J Biomed Sci. 2024; 81:11835.

PMID: 38450253 PMC: 10914946. DOI: 10.3389/bjbs.2024.11835.


Investigating the association between dental age and polymorphisms in genes encoding estrogen receptors.

Madalena I, Reis C, Matsumoto M, Stuani M, Mattos N, Oliveira D J Appl Oral Sci. 2023; 31:e20230184.

PMID: 37792810 PMC: 10547381. DOI: 10.1590/1678-7757-2023-0184.


References
1.
Sapkota Y . Germline DNA variations in breast cancer predisposition and prognosis: a systematic review of the literature. Cytogenet Genome Res. 2014; 144(2):77-91. DOI: 10.1159/000369045. View

2.
Smith R, Andrews K, Brooks D, Fedewa S, Manassaram-Baptiste D, Saslow D . Cancer screening in the United States, 2019: A review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin. 2019; 69(3):184-210. DOI: 10.3322/caac.21557. View

3.
Hu Z, Song C, Lu J, Luo J, Shen Z, Huang W . A multigenic study on breast cancer risk associated with genetic polymorphisms of ER Alpha, COMT and CYP19 gene in BRCA1/BRCA2 negative Shanghai women with early onset breast cancer or affected relatives. J Cancer Res Clin Oncol. 2007; 133(12):969-78. DOI: 10.1007/s00432-007-0244-7. View

4.
Thompson D, Easton D . Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst. 2002; 94(18):1358-65. DOI: 10.1093/jnci/94.18.1358. View

5.
Molina-Montes E, Perez-Nevot B, Pollan M, Sanchez-Cantalejo E, Espin J, Sanchez M . Cumulative risk of second primary contralateral breast cancer in BRCA1/BRCA2 mutation carriers with a first breast cancer: A systematic review and meta-analysis. Breast. 2014; 23(6):721-42. DOI: 10.1016/j.breast.2014.10.005. View